|
Physiomics PLC - oncology consultancy based in Oxford - Confirms it will continue to collaborate with DoseMeRx, after Tabula Rasa Healthcare Inc announces it will sell DoseMeRx. The collaboration will explore further commercial opportunities in cancer field. Over 2021, Physiomics' personalised dosing application for docetaxel prostate cancer treatment was integrated into DoseMeRx platform, and was met with positive feedback.
"Physiomics continues to work with DoseMeRx and looks forward to further developing the collaboration with DoseMeRx's new owners as and when the transaction is completed," the company says.
Current stock price: 5.48 pence, up 5.4% on Monday
12-month change: down 30%
By Elizabeth Winter; elizabethwinter@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
